Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Hum Hypertens ; 16 Suppl 1: S128-32, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11986910

RESUMO

Non-modulating is a highly reproducible type of sodium-sensitive hypertension. The aim of this study was to evaluate in non-modulating individuals the erythrocyte sodium-lithium countertransport (SLC) abnormalities, which have been mentioned as a marker of non-modulation, and the association with increased microalbuminuria, as a marker of an early kidney impairment. We measured erythrocyte SLC in 10 normotensives (NT, 28 +/- 4 years), 20 offspring of hypertensive parents being 10 modulating (MHO, 25 +/- 6 years) and 10 non-modulating (NMHO, 26 +/- 5 years), and 23 essential hypertensives being 12 modulating (MHT, 34 +/- 5 years) and 11 non-modulating (NMHT, 32 +/- 4 years). In all the subjects studied, microalbuminuria was determined by duplicate 24-h urine collection by radioimmunoassay. In non-modulating offspring of hypertensive parents and essential hypertensives. SLC was significantly elevated when compared either with normotensives without family history of hypertension, modulating offspring of hypertensive parents or essential hypertensives (P < 0.025). Likewise, 24-h urinary albumin excretion was found higher in non-modulating individuals (essential hypertensives and offspring of hypertensive parents) than in modulating individuals (P < 0.01). In conclusion, non-modulators with higher SLC countertransport sodium transport abnormalities showed higher elimination of microalbuminuria suggesting that non-modulators may have an increased risk for developing cardiovascular morbidity and kidney impairment even in normotensive subjects with familiarity history of hypertension.


Assuntos
Albuminúria/complicações , Antiporters/metabolismo , Eritrócitos/metabolismo , Hipertensão/genética , Hipertensão/metabolismo , Adulto , Análise de Variância , Transporte Biológico , Feminino , Humanos , Hipertensão/complicações , Masculino , Fatores de Risco , Estatísticas não Paramétricas
2.
Curr Hypertens Rep ; 3(2): 100-6, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11276389

RESUMO

The metabolic syndrome is a complex association of several risk factors including insulin resistance, dyslipidemia, and essential hypertension. Insulin resistance has been associated with sympathetic activation and endothelial dysfunction, which are the main mechanisms involved in the pathophysiology of hypertension and its related cardiovascular risk. According to the Sixth Report of the Joint National Committee, and guidelines of the World Health Organization/International Society of Hypertension, the presence of multiple risk markers suggests that both hypertension and risk factors should be aggressively managed in order to obtain a better outcome. Primary prevention of obesity at different levels--individual, familial, and social-- starting early in childhood has proven to be cost effective, and will be mandatory to reduce the world epidemic of obesity and its severe consequences.


Assuntos
Doenças Cardiovasculares/fisiopatologia , Hipertensão/fisiopatologia , Doenças Metabólicas/etiologia , Humanos , Fatores de Risco
3.
Med Prog Technol ; 21 Suppl: 5-11, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9413823

RESUMO

Knowledge about the viscoelastic behaviour of the arterial wall has been proved to have physiological importance and clinical usage. Our purpose was to study the changes of the systemic arterial wall's elastic properties non-invasively, in patients with established essential and with borderline hypertension, and to evaluate its possible determinants. Three groups of normotensive, borderline and established essential hypertensive patients were evaluated. Arterial pulse wave velocity (PWV) was measured and arterial compliance (Cm) was derived in all patients. Pulse wave velocity was obtained from the pressure values of digitized carotid and radial arteries. Arterial compliance (Cm = dD/dP with P pressure and D diameter) was calculated using a formula derived from the Bramwell and Hill equation: Cm = (1,334 x D)/(2 rho x PWV2), where for D humeral diameter was used as measured by high resolution echograph, and rho is the blood density (rho = 1.06). Pulse wave velocity was significantly higher in established essential hypertensive patients with respect to normotensive patients (p < 0.05). Arterial compliance was significantly diminished in established and in borderline hypertensive patients with respect to normotensive patients (p < 0.05), which implies early alterations in hypertensive cardiovascular disease. Multiple regression analysis of the cofactors showed that age and diastolic pressure are independent determinants of Cm. Impairment of the arterial wall's intrinsic elastic properties was demonstrated in established essential hypertension, independent of age and diastolic pressure.


Assuntos
Artérias/fisiopatologia , Hipertensão/fisiopatologia , Adolescente , Adulto , Fatores Etários , Idoso , Algoritmos , Artérias/diagnóstico por imagem , Artérias/patologia , Velocidade do Fluxo Sanguíneo/fisiologia , Pressão Sanguínea/fisiologia , Viscosidade Sanguínea/fisiologia , Artéria Carótida Primitiva/diagnóstico por imagem , Artéria Carótida Primitiva/patologia , Artéria Carótida Primitiva/fisiopatologia , Diástole , Elasticidade , Feminino , Frequência Cardíaca/fisiologia , Humanos , Úmero/irrigação sanguínea , Úmero/diagnóstico por imagem , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Fluxo Pulsátil/fisiologia , Artéria Radial/diagnóstico por imagem , Artéria Radial/patologia , Artéria Radial/fisiopatologia , Ultrassonografia , Capacitância Vascular/fisiologia , Viscosidade
4.
Cardiology ; 83(1-2): 76-81, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8261491

RESUMO

Thirty patients (18 male), mean age 49.5 +/- 6.3 years, were treated with lisinopril 10-40 mg once daily for 16 weeks. The effect of treatment on left ventricular mass and improvement in left ventricular diastolic function (measured by echo-Doppler) was assessed. Blood pressure changes were measured conventionally in the clinic and by ambulatory blood pressure monitoring. Clinic blood pressure decreased from 168.3 +/- 13.8/105.5 +/- 5.4 mm Hg to 137.5 +/- 4.1/88.8 +/- 4.1 mm Hg (p < 0.005 for both systolic and diastolic blood pressures), and the heart rate from 75.2 +/- 3.7 to 74.4 +/- 7.6 beats per minute (NS). The frequency of ambulatory systolic blood pressure values > 140 mm Hg decreased in percentage from 63.3 +/- 12.8 to 29.9 +/- 9.1% (p < 0.005) and the frequency of ambulatory diastolic blood pressure values > 90 mm Hg decreased in percentage from 61.1 +/- 12.8 to 28.6 +/- 7.5% (p < 0.005). Septal and left ventricular posterior wall thickness decreased from 11.2 +/- 0.9 to 10.3 +/- 0.6 mm and from 10.9 +/- 0.9 to 10.1 +/- 0.6 mm, respectively (both p < 0.005). Left ventricular diastolic diameter and the shortening fraction did not change significantly. Left ventricular mass, calculated from left ventricular wall thickness and diastolic diameter, decreased from 132.6 +/- 11.5 to 119.9 +/- 6.3 g/m2 (p < 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Volume Cardíaco/efeitos dos fármacos , Diástole/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Lisinopril/uso terapêutico , Função Ventricular Esquerda/efeitos dos fármacos , Adulto , Monitores de Pressão Arterial , Volume Cardíaco/fisiologia , Diástole/fisiologia , Relação Dose-Resposta a Droga , Ecocardiografia Doppler/efeitos dos fármacos , Feminino , Hemodinâmica/efeitos dos fármacos , Hemodinâmica/fisiologia , Humanos , Hipertensão/diagnóstico por imagem , Hipertensão/fisiopatologia , Hipertrofia Ventricular Esquerda/diagnóstico por imagem , Hipertrofia Ventricular Esquerda/fisiopatologia , Masculino , Pessoa de Meia-Idade , Função Ventricular Esquerda/fisiologia
5.
Hypertension ; 19(2 Suppl): II129-31, 1992 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-1735566

RESUMO

This study assessed the effectiveness of atenolol in the treatment of moderate and severe hypertension during pregnancy. Seventy patients (mean age, 30.3 +/- 6.0 years), 35.7% primiparous, were included. Three groups were formed according to Davey and MacGillivray's classification: 1) chronic hypertension without proteinuria (12 patients), 2) gestational hypertension without proteinuria (52 patients), and 3) preeclampsia (six patients). Treatment with atenolol was started when blood pressure was 150/100 mm Hg or higher after 48 hours' rest. The treatment lasted at least 1 week; follow-up was every 2 weeks up to week 36, and from then on, weekly up to delivery. If blood pressure exceeded 160/110 mm Hg and the fetus was not yet mature, a second drug was added. A significant decrease in blood pressure was observed in the three groups (group 1: 155.8 +/- 15.0/100.8 +/- 7.6 versus 135.0 +/- 12.9/85.0 +/- 6.7 mm Hg; group 2: 154.2 +/- 13.6/104.9 +/- 9.3 versus 129.6 +/- 10.2/83.7 +/- 9.1 mm Hg; group 3: 158.3 +/- 27.1/104.1 +/- 8.0 versus 129.1 +/- 6.6/87.5 +/- 6.1 mm Hg). The doses of atenolol were 62.5 +/- 23.0 mg/day in group 1, 70.0 +/- 30.0 mg/day in group 2, and 100.0 +/- 41.0 mg/day in group 3. There was no fetal mortality. No significant difference occurred in newborn body weights. Four babies from group 2 mothers had an Apgar score of less than 7 at 1 minute, but only one remained abnormal after 5 minutes. In the same group, three cases of respiratory distress were observed.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Atenolol/uso terapêutico , Hipertensão/tratamento farmacológico , Complicações Cardiovasculares na Gravidez/tratamento farmacológico , Adulto , Feminino , Humanos , Paridade , Gravidez
6.
Hypertension ; 15(2 Suppl): I153-6, 1990 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-2298471

RESUMO

Exercise might reduce blood pressure in mild essential hypertensive individuals, but it could raise left ventricular mass, counteracting the beneficial effects induced by a decrease in blood pressure. Seventeen (group 1) of 25 mild hypertensive patients, nonresponders to a 3-month low sodium diet (2 g/day), were admitted into a physical training program consisting of three weekly sessions of aerobics (20 minutes), bicycling at prefixed loads (20 minutes), and induced muscular relaxation (10 minutes). They were compared with 15 mild hypertensive patients (group 2), nonresponders to the low sodium diet who remained untrained. The follow-up lasted 15.7 +/- 5.8 months. There were significant blood pressure decreases in group 1 at rest (155 +/- 9.8/101 +/- 3.3 vs. 136 +/- 8.1/86 +/- 6.6 mm Hg, p less than 0.001) and at maximal effort (219 +/- 27.4/119 +/- 14.4 vs. 196 +/- 21.8/101 +/- 10.5 mm Hg, p less than 0.001). Maximal work capacity increased from 758.8 +/- 256.7 to 944.1 +/- 203.8 kpm (p less than 0.001). Echocardiographic left ventricular mass index tended to decrease (137.8 +/- 36.3 vs. 125.4 +/- 29.9 g/m2, p = NS), without any significant modification of either left ventricular volume index or left ventricular shortening fraction. No significant changes occurred in group 2. There was no correlation between blood pressure and left ventricular mass changes and left ventricular shortening fraction and left ventricular mass index changes. According to these results, it seems prudent to prescribe physical training to mild hypertensive patients because it does not induce left ventricular mass increases.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Hipertensão/patologia , Miocárdio/patologia , Educação Física e Treinamento , Pressão Sanguínea , Volume Sanguíneo , Diástole , Teste de Esforço , Feminino , Coração/fisiopatologia , Frequência Cardíaca , Ventrículos do Coração , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade
7.
Medicina (B Aires) ; 50(3): 217-24, 1990.
Artigo em Espanhol | MEDLINE | ID: mdl-2151823

RESUMO

Changes in left ventricular mass (LVM) were measured by echocardiography in 104 mild and moderate essential hypertensives treated with only one drug for at least 12 months. They were classified into 4 groups. G1: 40 patients (p) treated with atenolol (73.6 +/- 31.8 mg daily), G2: 32 p treated with enalapril maleate (17.7 +/- 8.7 mg daily), G3: 22 p treated with nifedipine (44.0 +/- 10.8 mg daily), G4: control group, 10 mild hypertensives without medication. At the end of the treatment blood pressure (BP) fell significantly in the first 3 groups (G1: 155 +/- 19/.98 +/- 11 vs. 136 +/- 11/86 +/- 15 mm Hg, G2: 163 +/- 19/104 +/- 10 vs. 139 +/- 12/90 +/- 8 mm Hg, G3: 166 +/- 17/103 +/- 7 vs. 142 +/- 7/85 +/- 7 mm Hg, p less than 0.001), but remained unchanged in G4. Heart rate was reduced significantly only in G1. Body weight did not change (71 +/- 7 vs. 67 +/- 7, p greater than .05). Patients were subclassified according to wether they had normal (N, LVM less than 120 g/m2 in females, LVm less than 135 g/m2 in males) or increased (H) LVM. There was a significant reduction in LVM in all H subgroups (G1 163 +/- 37 vs. 131 +/- 27 g/m2, G2: 155 +/- 19 vs. 126 +/- 21 g/m2, G3: 158 +/- 2 vs. 138 +/- 38 g/m2, p less than .005). The LVM/left ventricular end-diastolic volume ratio (M/V) fell in all H subgroups.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Atenolol/uso terapêutico , Cardiomegalia/tratamento farmacológico , Enalapril/uso terapêutico , Hipertensão/tratamento farmacológico , Adulto , Pressão Sanguínea/efeitos dos fármacos , Cardiomegalia/etiologia , Esquema de Medicação , Feminino , Humanos , Hipertensão/complicações , Masculino , Pessoa de Meia-Idade , Projetos de Pesquisa
8.
Medicina [B Aires] ; 50(3): 217-24, 1990.
Artigo em Espanhol | BINACIS | ID: bin-51550

RESUMO

Changes in left ventricular mass (LVM) were measured by echocardiography in 104 mild and moderate essential hypertensives treated with only one drug for at least 12 months. They were classified into 4 groups. G1: 40 patients (p) treated with atenolol (73.6 +/- 31.8 mg daily), G2: 32 p treated with enalapril maleate (17.7 +/- 8.7 mg daily), G3: 22 p treated with nifedipine (44.0 +/- 10.8 mg daily), G4: control group, 10 mild hypertensives without medication. At the end of the treatment blood pressure (BP) fell significantly in the first 3 groups (G1: 155 +/- 19/.98 +/- 11 vs. 136 +/- 11/86 +/- 15 mm Hg, G2: 163 +/- 19/104 +/- 10 vs. 139 +/- 12/90 +/- 8 mm Hg, G3: 166 +/- 17/103 +/- 7 vs. 142 +/- 7/85 +/- 7 mm Hg, p less than 0.001), but remained unchanged in G4. Heart rate was reduced significantly only in G1. Body weight did not change (71 +/- 7 vs. 67 +/- 7, p greater than .05). Patients were subclassified according to wether they had normal (N, LVM less than 120 g/m2 in females, LVm less than 135 g/m2 in males) or increased (H) LVM. There was a significant reduction in LVM in all H subgroups (G1 163 +/- 37 vs. 131 +/- 27 g/m2, G2: 155 +/- 19 vs. 126 +/- 21 g/m2, G3: 158 +/- 2 vs. 138 +/- 38 g/m2, p less than .005). The LVM/left ventricular end-diastolic volume ratio (M/V) fell in all H subgroups.(ABSTRACT TRUNCATED AT 250 WORDS)

9.
Medicina [B.Aires] ; 50(3): 217-24, 1990. tab
Artigo em Espanhol | BINACIS | ID: bin-27656

RESUMO

En 104 hipertensos esenciales leves y moderados se midieron mediante ecocardiografía los cambios inducidos en la masa ventricular izquierda (MV) por el tratamiento con monodrogas durante por lo menos 12 meses. Los pacientes (p) fueron clasificados en 4 grupos (G). G1: 40p tratados con atenolol, G2: 32p tratados con maleato de enalapril, G3: 22p tratados cocn nifedipina, G4: grupo control, 10 en los primeros 3 grupos, pero no se modificó en el G4. La frecuencia cardíaca se redujo significativamente solo en el G1. El peso corporal no varió. Los pacientes fueron subclasificados de acuerdo a que su MV fuese normal (N, MV, < 120 g/m2 en hombres) o aumentada (H). Hubo una reducción significativa de la MV en todos los grupos H. La relación MV/volumen de fin de diastole del ventrículo izquierdo (M/V) cayó en todos los grupos H. Hubo una correlación pequeña, aunque significativa entre la PA vbasal y la MV. La regresión de la MV fue mayor en los ventrículos hipertróficos, sin que se produjesen cambios significativos en a fracción de acortamiento. En base a estos resultados parecería razonable elegir para el tratamiento las drogas antihipertensivas que reduzcan la MV (AU)


Assuntos
Humanos , Masculino , Feminino , Hipertensão/tratamento farmacológico , Atenolol/uso terapêutico , Enalapril/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Cardiomegalia/tratamento farmacológico , Grupos Controle , Esquema de Medicação , Hipertensão/complicações , Cardiomegalia/etiologia
10.
Medicina (B.Aires) ; 50(3): 217-24, 1990. tab
Artigo em Espanhol | LILACS | ID: lil-95104

RESUMO

En 104 hipertensos esenciales leves y moderados se midieron mediante ecocardiografía los cambios inducidos en la masa ventricular izquierda (MV) por el tratamiento con monodrogas durante por lo menos 12 meses. Los pacientes (p) fueron clasificados en 4 grupos (G). G1: 40p tratados con atenolol, G2: 32p tratados con maleato de enalapril, G3: 22p tratados cocn nifedipina, G4: grupo control, 10 en los primeros 3 grupos, pero no se modificó en el G4. La frecuencia cardíaca se redujo significativamente solo en el G1. El peso corporal no varió. Los pacientes fueron subclasificados de acuerdo a que su MV fuese normal (N, MV, < 120 g/m2 en hombres) o aumentada (H). Hubo una reducción significativa de la MV en todos los grupos H. La relación MV/volumen de fin de diastole del ventrículo izquierdo (M/V) cayó en todos los grupos H. Hubo una correlación pequeña, aunque significativa entre la PA vbasal y la MV. La regresión de la MV fue mayor en los ventrículos hipertróficos, sin que se produjesen cambios significativos en a fracción de acortamiento. En base a estos resultados parecería razonable elegir para el tratamiento las drogas antihipertensivas que reduzcan la MV


Assuntos
Humanos , Masculino , Feminino , Atenolol/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Cardiomegalia/tratamento farmacológico , Enalapril/uso terapêutico , Hipertensão/tratamento farmacológico , Cardiomegalia/etiologia , Grupos Controle , Esquema de Medicação , Hipertensão/complicações
11.
Z Kardiol ; 74 Suppl 2: 19-23, 1985.
Artigo em Inglês | MEDLINE | ID: mdl-4002798

RESUMO

A multi-center open trial was carried out with 103 patients with chronic congestive heart failure (CHF) of diverse etiologies with oedemas, 25 with hepatomegalia, placed in classes II or III of NYHA functional capacity, with increasing doses of 30, 60 and 90 mg of muzolimine qd to ascertain (1) the effective dose for the elimination of oedemas and hepatomegalia and (2) whether such a dose keeps its efficacy throughout a long administration period. After a wash-out period of 3-7 days, heart rate (HR), systolic (SBP) and diastolic blood pressure (DBP) in supine and standing positions, body weight (BW) and 24 hour diuresis were controlled and laboratory tests were performed. Muzolimine was administered and an assessment of the therapeutic effect was carried out every week. When the clinical results were ineffective, the dose was increased weekly up to 90 mg. When the results were partial, the same dose was given for another week and when it was effective the search for the dose was concluded. Out of the 103 patients, 67 needed only 30 mg of muzolimine for an effective elimination of oedemas and hepatomegalia, 32 needed 60 mg and only 4 had to have the dose increased to 90 mg to obtain efficacy. The SBP and DBP diminished by 6.3% and 7.2% respectively, and HR was reduced, though not significantly. BW diminished an average of 2.4 Kg and the diuresis increased significantly from a mean value of 1.043 ml/24 h to 1.714 ml/24 h. Sixty-two patients with effective results agreed to undergo chronic treatment for 24 weeks and be controlled every 2 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Insuficiência Cardíaca/tratamento farmacológico , Muzolimina/administração & dosagem , Pirazóis/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Doença Crônica , Diurese/efeitos dos fármacos , Edema/tratamento farmacológico , Feminino , Insuficiência Cardíaca/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Hepatomegalia/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Muzolimina/uso terapêutico , Fatores de Tempo
12.
J Cardiovasc Pharmacol ; 6 Suppl 7: S1096-9, 1984.
Artigo em Inglês | MEDLINE | ID: mdl-6085374

RESUMO

Thirty-seven white patients of both sexes were studied to determine the efficacy and tolerance of nitrendipine for long ambulatory treatment in patients suffering from mild to moderate essential arterial hypertension whose response to the drug had been effective in a previous study. They all suffered from mild essential arterial hypertension, with diastolic arterial blood pressure (DBP) of 95-104 mm Hg, and moderate arterial hypertension with DBP of 105-114 mm Hg, in WHO Stage I or II, according to the clinical, radiological, electrocardiographic, and ophthalmoscopic examinations. In a previous study, all of them had been subjected to tensional controls, performed hourly during an 8-h period to assess their hypertension. Later, they were treated with increasing doses of nitrendipine, administered once or twice daily, until DBP figures under 90 mm Hg were obtained in at least five of the eight controls of each daily profile. All of them agreed to take part in the present research and underwent heart rate and arterial blood pressure controls in supine and standing position every 14 days during 24 periods. Simultaneous clinical and weight controls were performed. Moreover, an electrocardiogram was made every 28 days, and blood and urine tests were performed every 3 months. Of the 37 patients, 31 completed the 24 periods of 2 weeks each. Therefore, of 888 possible controls only 837 controls were made and submitted for assessment. Eighteen patients (48.6%) went on with the initial dose throughout the study or were able to reduce it. Eleven (29.7%) had to increase it, and in eight cases (21.6%) it was either increased or reduced.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Bloqueadores dos Canais de Cálcio/uso terapêutico , Hipertensão/tratamento farmacológico , Nifedipino/análogos & derivados , Adulto , Idoso , Pressão Sanguínea/efeitos dos fármacos , Bloqueadores dos Canais de Cálcio/efeitos adversos , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Nifedipino/efeitos adversos , Nifedipino/uso terapêutico , Nitrendipino , Postura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...